A new drug that combines Actos with an angiotensin receptor blocker called TAK-536 has entered into Phase III clinical trials in the United States, Takeda Pharmaceuticals has reported. The drug is designed to control both glucose levels and hypertension in patients with Type 2 diabetes. Approximately 60 percent of patients in the U.S. who have diabetes also have hypertension.
Read moreThe past year was a big one in hypertension. A number of trials were reported at meetings and in the medical literature with great... Read more »
Congestive heart failure (CHF) is one of the most common reasons for hospital admission in the United States and most Western European... Read more »
Dad, Mom and I all have hypertension. We each have different doctors and different medicines. Why? You and your parents are among the... Read more »
A new drug called darusentan has shown promise for treating people with hard-to-treat high blood pressure in a pivotal clinical trial. In the study,... Read more »
(Ivanhoe Newswire) -- Turning serendipity into science, researchers at the Stanford University School of Medicine have found that a safe, inexpensive... Read more »
The U.S. Food and Drug Administration has approved the med Letairis to treat a life-threatening condition called pulmonary arterial hypertension.... Read more »
Officials with the International Society of Hypertension in Blacks are calling for earlier and more aggressive intervention for the black community,... Read more »
This is a study to test the safety and effectiveness of a new device, the Rheos Baroreflex Hypertension System, in people whose high blood pressure... Read more »